Proceedings of the National Academy of Sciences · 2006 · 199 citations · 23 references
MedicineMolecular BiologyOncologyMetastasisMolecular OncologyTumor ProgressionCancer Cell SignalingCancer ProgressionMalignant NeoplasmsMetastatic Signaling PathwaysProstate CancerSignal Transduction In CancerMatrix Metalloproteinase Gene ExpressionMatrix Metalloproteinase Gene RegulationMatrix Metalloproteinase Transcriptional ControlMetastatic InvasionMetastatic MechanismsProteolytic PathwaysS100 Protein ExpressionTranscriptional Activation
We previously showed that the calcium-binding protein S100A4 is overexpressed during the progression of prostate cancer (CaP) in humans and in the TRAMP (transgenic adenocarcinoma of the mouse prostate) mouse model. We tested a hypothesis that the S100A4 gene plays a role in the invasiveness of human CaP and may be associated with its metastatic spread. We observed that siRNA-mediated suppression of the S100A4 gene significantly reduced the proliferative and invasive capability of the highly invasive CaP cells PC-3. We evaluated the mechanism through which the S100A4 gene controls invasiveness of cells by using a macroarray containing 96 well characterized metastatic genes. We found that matrix metalloproteinase 9 (MMP-9) and its tissue inhibitor (TIMP-1) were highly responsive to S100A4 gene suppression. Furthermore, S100A4 suppression significantly reduced the expression and proteolytic activity of MMP-9. By employing an MMP-9-promoter reporter, we observed a significant reduction in the transcriptional activation of the MMP-9 gene in S100A4-siRNA-transfected cells. Cells overexpressing the S100A4 gene (when transfected with pcDNA3.1-S100A4 plasmid) also significantly expressed MMP-9 and TIMP-1 genes with increased proteolytic activity of MMP-9 concomitant to increased transcriptional activation of the MMP-9 gene. S100A4-siRNA-transfected cells exhibited a reduced rate of tumor growth under in vivo conditions. Our data demonstrate that the S100A4 gene controls the invasive potential of human CaP cells through regulation of MMP-9 and that this association may contribute to metastasis of CaP cells. We suggest that S100A4 could be used as a biomarker for CaP progression and a novel therapeutic or chemopreventive target for human CaP treatment.
23
Ahmedin Jemal, Rebecca L. Siegel, Elizabeth M. Ward et al. · CA A Cancer Journal for Clinicians · 2006 · 5.3K citations · Full text
Kristin Bjørnland, Jan Winberg, Eivind Hovig et al. · PubMed · 1999 · 169 citations
Medicine, Cancer Biology, Oncology +13
ERBB2 up-regulates S100A4 and several other prometastatic genes in medulloblastoma.
Roberto Hernán, Rami Fasheh, Christopher Calabrese et al. · PubMed · 2003 · 169 citations